| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
150,780,000 |
| Market
Cap: |
59.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3938 - $0.3938 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
51,839 |
| Total Sell Value |
$0 |
$0 |
$0 |
$9,588 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schroeder Theodore R |
Chief Executive Officer |
• • – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
343,800 |
646,560 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
180,830 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
183,669 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
188,097 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$5,798 |
D/D |
(4,295) |
78,669 |
|
- |
|
| Gelone Steven P. |
President & COO |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$11,679 |
D/D |
(8,651) |
171,919 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$5,254 |
D/D |
(3,892) |
75,830 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$5,254 |
D/D |
(3,892) |
83,097 |
|
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2020-01-31 |
4 |
D |
$1.35 |
$21,973 |
D/D |
(16,276) |
302,760 |
|
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$5,798 |
D/D |
(4,295) |
53,705 |
|
- |
|
| Broom Colin Md |
Director |
– • – |
2019-08-30 |
4 |
B |
$2.03 |
$20,668 |
D/D |
10,177 |
208,750 |
2.39 |
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2019-08-27 |
4 |
B |
$1.79 |
$89,500 |
I/I |
50,000 |
117,489 |
2.66 |
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2019-08-22 |
4 |
B |
$2.04 |
$9,780 |
D/D |
4,800 |
15,972 |
2.74 |
- |
|
| Gelone Steven P. |
President & COO |
• – – |
2019-08-21 |
4/A |
S |
$2.08 |
$17,068 |
D/D |
(8,206) |
47,570 |
|
- |
|
| Broom Colin Md |
Director |
– • – |
2019-08-21 |
4/A |
S |
$2.07 |
$21,066 |
D/D |
(10,177) |
125,724 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2019-08-21 |
4/A |
S |
$2.08 |
$7,051 |
D/D |
(3,390) |
19,214 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2019-08-21 |
4/A |
S |
$2.08 |
$7,898 |
D/D |
(3,797) |
11,172 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2019-08-21 |
4/A |
S |
$2.08 |
$7,898 |
D/D |
(3,797) |
23,239 |
|
- |
|
| Broom Colin Md |
Director |
– • – |
2019-08-21 |
4 |
D |
$2.07 |
$21,066 |
D/D |
(10,177) |
125,724 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2019-08-21 |
4 |
D |
$2.08 |
$7,898 |
D/D |
(3,797) |
23,239 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2019-08-21 |
4 |
D |
$2.08 |
$7,051 |
D/D |
(3,390) |
19,214 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2019-08-21 |
4 |
D |
$2.08 |
$7,898 |
D/D |
(3,797) |
11,172 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2019-08-21 |
4 |
D |
$2.08 |
$17,068 |
D/D |
(8,206) |
47,570 |
|
- |
|
| Broom Colin Md |
Director |
– • – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,750 |
135,901 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
27,036 |
|
- |
|
323 Records found
|
|
Page 10 of 13 |
|
|
